2023
Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding. Blood 2023, 142: 2312. DOI: 10.1182/blood-2023-185340.Peer-Reviewed Original ResearchHereditary hemorrhagic telangiectasiaIncremental net monetary benefitIncremental cost-effectiveness ratioEmergency department visitsCare of patientsHemostatic proceduresIron infusionPatient timeBevacizumab therapyDepartment visitsRBC transfusionHemorrhagic telangiectasiaVascular endothelial growth factor inhibitionRed blood cell transfusionEQ-5D index valuesCommon hereditary bleeding disorderLocal hemostatic proceduresRBC transfusion needSystemic bevacizumab therapyHealth resource utilizationBlood cell transfusionWorld Health Organization VigiBaseLong-term followGrowth factor inhibitionCost-saving intervention
2021
Analysis of Electronic Health Record Use and Clinical Productivity and Their Association With Physician Turnover
Melnick ER, Fong A, Nath B, Williams B, Ratwani RM, Goldstein R, O’Connell R, Sinsky CA, Marchalik D, Mete M. Analysis of Electronic Health Record Use and Clinical Productivity and Their Association With Physician Turnover. JAMA Network Open 2021, 4: e2128790. PMID: 34636911, PMCID: PMC8511970, DOI: 10.1001/jamanetworkopen.2021.28790.Peer-Reviewed Original ResearchConceptsElectronic health recordsPhysician turnoverRetrospective cohort studyElectronic health record usePractice networkPhysician productivityWarrants further investigationCohort studyEHR timeAge 45Care teamPhysician departurePhysician ordersMAIN OUTCOMEHigh riskPatient timeAmbulatory physiciansPatient volumeUnique physiciansRecord useEHR useHealth care organizationsPhysiciansHealth recordsClinical timeCharacterizing physician EHR use with vendor derived data: a feasibility study and cross-sectional analysis
Melnick ER, Ong SY, Fong A, Socrates V, Ratwani RM, Nath B, Simonov M, Salgia A, Williams B, Marchalik D, Goldstein R, Sinsky CA. Characterizing physician EHR use with vendor derived data: a feasibility study and cross-sectional analysis. Journal Of The American Medical Informatics Association 2021, 28: 1383-1392. PMID: 33822970, PMCID: PMC8279798, DOI: 10.1093/jamia/ocab011.Peer-Reviewed Original ResearchConceptsElectronic health recordsEHR timeCross-sectional analysisAmbulatory physiciansPatient timeHealth systemClinical hoursHours of patientsMedStar Health systemYale-New HavenObstetrics/gynecologyNeurology/psychiatryMultivariable analysisPhysician genderCertain medical specialtiesPhysical medicineFemale physiciansEHR usePhysiciansHealth recordsHealthcare systemMedical specialtiesHoursSpecialtiesGenderA quasiexperimental study of targeted normoxia in critically ill trauma patients
Dylla L, Anderson E, Douin D, Jackson C, Rice J, Schauer S, Neumann R, Bebarta V, Wright F, Ginde A. A quasiexperimental study of targeted normoxia in critically ill trauma patients. Journal Of Trauma And Acute Care Surgery 2021, 91: s169-s175. PMID: 33797494, PMCID: PMC9709909, DOI: 10.1097/ta.0000000000003177.Peer-Reviewed Original ResearchConceptsCritically Ill Trauma PatientsPostintervention subjectsPostintervention periodTrauma patientsTargeted normoxiaIntervention increased adherenceSupplemental oxygenChronic Health Evaluation II scoreEmergency department arrivalNeurosurgical intensive care unitMilitary trauma patientsIntensive care unitCOnsensus-basedQuasiexperimental studyPostinterventionLevels of FiO2Acute PhysiologyPatient timeII scoreClinical outcomesMm HgTherapeutic/care managementAvoidance of hypoxiaReduce morbidityPrimary outcome
2011
The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s76-s82. PMID: 21317599, PMCID: PMC3270565, DOI: 10.1097/qai.0b013e31820a9a66.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentIntegrated care patientsBuprenorphine/naloxoneNaloxone treatmentCare patientsClinic costsIntegrated careCross-site evaluationHIV clinical sitesIntegrated HIV careUrine toxicology analysisMedian monthly costPotential cost offsetsToxicology analysisHIV careIntegrated HIVSimilar patientsPhysician encountersPatient costsClinic settingMedian numberProvider encountersPatient timePatientsClinical sites
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply